Introduction
Hemorrhagic cystitis (HC) is a well-recognized complication of hematopoietic stem cell transplantation (HSCT) in children and adolescents. The etiology is often multifactorial and includes cyclophosphamide toxicity, irradiation, acute graft-versus-host disease (GvHD) and viruses (adenovirus, polyoma BK virus and cytomegalovirus). 1 In addition, the event is often precipitated and exacerbated by thrombocytopenia. Clinically, its severity ranges from asymptomatic micro-hematuria to macro-hematuria with clots, painful bladder spasm and even urinary tract obstruction. The time course varies from a mild, transient condition to a chronic debilitating problem with significant medical and psychological impacts. Unfortunately, despite many different therapies being described, no definitive treatment has been established. Recently, encouraging results using conjugated estrogens have been described in adults. 2 We describe our use of this modality in children and adolescents suffering HC following HSCT.
Patients and methods
Ten cases of HC following high-dose chemotherapy and HSCT in children and adolescents treated at the Children's Cancer Centre, Royal Children's Hospital between 1 January 1998 and 1 January 2004 are reported. The clinical characteristics of the patients are listed in Table 1 . All patients had received cyclophosphamide (120 mg/m 2 ) with mesna as part of their conditioning regimen. The majority of patients (all except cases 7 and 9) had also received total body irradiation (12 Gy). The severity of HC was graded according to the previously reported Bearman scale. 3 A summary of the patients' status at the time of presentation with hematuria is listed in Table 2 . Patients who suffered HC were routinely hyper-hydrated and transfused platelets to maintain the platelet count above 50 Â 10 9 /l. Patients were required to have a serum bilirubin less than 100 mM/l prior to the commencement of estrogen. The conjugated estrogen product used was Premarin (Ayerst Laboratories). All patients receiving estrogen were assessed clinically for potential side effects/toxicities daily, and had their liver function assessed at least every 48 h.
Results
Seven male and three female patients aged between 8 and 19 years of age were treated. There were three related and seven unrelated HSCT: two antigen-mismatched cord blood transplants and eight matched BMT. Most patients also suffered associated abdominal pain, dysuria and polyuria. All patients were thrombocytopenic at the onset of symptoms (range 10-26 Â 10 9 /l). Despite this, four patients developed clots and in two this resulted in urinary tract obstruction. Five patients were suffering acute GvHD at the onset of their symptoms. Urinary viral cultures were positive in six patients, five with polyoma BK virus, two with CMV and one with adenovirus.
A summary of treatments and response to episodes of HC are summarized in Table 3 . Patients were usually started on intravenous estrogen and transferred to oral estrogen after 2 or 3 days. The duration of estrogen administration varied from 5 to 23 days. Eight of the 10 patients had a significant reduction in their symptoms coincident with the first commencement of estrogen. Furthermore, there was complete resolution of macroscopic hematuria in the one patient with mild HC (100%) and five of the seven with severe HC (71%). In general, estrogen therapy was very well tolerated, with no episodes of flushing, hypertension, thrombosis or feminization in males recorded. One patient (patient five), who suffered from grade III liver GvHD at the commencement of estrogen therapy, had treatment ceased because of a rise in serum bilirubin. With resolution of the GvHD, this eventually returned to normal.
Discussion
HC continues to be a major problem for children and adolescents undergoing HSCT. The reported incidence in institutional series ranges from 15 to 40%. 4 Direct urothelial toxicity resulting from exposure to high levels of acrocyanin, a metabolite of cyclophosphamide, appears to be the most common mechanism. Additional contributing factors include exposure to viruses (adeno, CMV and polyoma BK virus in particular), radiation and acute GvHD. All of these toxicities are likely to be exacerbated by the presence of either thrombocytopenia or coagulation disorders, both of which are quite common in this patient cohort. Many different treatment options have been described previously. Initially, increased fluids and forced dieresis, together with platelet transfusions and correction of any coagulopathy, are usually instituted. Most patients also require analgesia and spamolytic drugs. Other noninvasive measures have included hyperbaric oxygen, prostaglandins 6 and estrogens. 2, [7] [8] [9] Where blood clots are being passed or where urinary tract obstruction is suspected, bladder washouts may also be required. Endoscope examination of the bladder lining with cauterization of bleeding mucosa may also be of benefit. More invasive techniques, such as installation of formalin or use of a pressure balloon, may be effective, but carry an increased risk of bladder retraction and incontinence. 10 In rare cases, cystostomy or cystectomy has been required. 11 The mechanism by which estrogens are thought to act is stabilization or micro-vasculature. A number of previous investigators have documented limited experience of estrogens in the treatment of HC in HSCT. Liu et al. reported five adults who responded to both intravenous and oral estrogen without complication, and Miller et al. 9 documented a successful outcome in six of seven adults (86%). Most recently, an encouraging report of a positive effect in seven of 10 adult patients (70%) was published. 2 Our results suggest that a similar efficacy can be expected in children and adolescents. There has been a single case report of treatment failure, notably in a case of severe bleeding. 9 Like all treatments, failure to respond is an indication to examine alternative interventions.
All patients tolerated the therapy without incident. The potential adverse effects of estrogen administration, which include liver dysfunction, hypercoagulability, hypertension and malignant transformation, were not observed. One patient had a rapid elevation in serum bilirubin, but this was in the context of grade III liver GvHD and sepsis and resolved without long-term problems.
In conclusion, we believe that estrogen is a worthwhile therapeutic option in the treatment of HC in children and adolescents following HSCT. Our data demonstrate the feasibility, safety and efficacy of this intervention. A larger multi-center trial is needed to confirm these preliminary results.
